Loading stock data…
IN8bio (INAB)
$1.43+0.07 (+5.15%)
After Hours$1.43+0.00 (+0.00%)· Last close Jun 29
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IN8bio, Inc. in the Healthcare sector is trading at $1.43 with a market capitalization of $14M. Wall Street consensus targets $6.25 (4 analysts), implying a +337.1% move over the next 12 months. The stock is currently near its 52-week low of $1.17, remaining 20.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +337.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.27M↓ | -$5.03M↓ | -$3.97M↑ | -$5.20M↑ | -$5.66M |
| Net Income | -$5.09M↓ | -$4.94M↓ | -$3.85M↑ | -$5.09M↑ | -$5.55M |
Peer Comparison
JNJUNHPFE
Fundamentals
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include I...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-83.32%
Volume
Today's trading volume
51,009
